We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-17.59%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
-$301M
Cap. Flow
+$247M
Cap. Flow %
16.82%
Top 10 Hldgs %
53.54%
Holding
70
New
19
Increased
8
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$84.4M
2
SAGE
Sage Therapeutics
SAGE
+$68.5M
3
BDTX icon
Black Diamond Therapeutics
BDTX
+$61.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$55.7M
5
AMRN
Amarin Corp
AMRN
+$37.4M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$82.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$29M
3
APLS
Apellis Pharmaceuticals
APLS
+$24.5M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$23.5M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$136M 9.25%
1,765,560
+50,000
+3% +$4.48M
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$114M 7.76%
8,450,000
– –
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$114M 7.76%
925,000
– –
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$92.9M 6.33%
3,363,377
– –
RVMD icon
5
Revolution Medicines
RVMD
$39.9B
$66.8M 4.55%
+3,049,764
New +$84.4M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$78.5B
$65.9M 4.49%
+135,000
New +$55.7M
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
$56M 3.82%
2,075,905
– –
BDTX icon
8
Black Diamond Therapeutics
BDTX
$96.8M
$50.3M 3.43%
+2,014,858
New +$61.3M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$46.2M 3.15%
400,000
-100,000
-20% -$11.1M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$44M 3%
1,532,510
+1,182,510
+338% +$68.5M
RCUS icon
11
Arcus Biosciences
RCUS
$3.55B
$42.8M 2.92%
3,084,883
+1,412,650
+84% +$17.6M
QURE icon
12
uniQure
QURE
$3.03B
$36.3M 2.48%
765,400
– –
ESPR
13
DELISTED
Esperion Therapeutics
ESPR
$30.7M 2.1%
975,000
– –
ALLK
14
DELISTED
Allakos
ALLK
$30M 2.05%
675,000
– –
PASG icon
15
Passage Bio
PASG
$14.4M
$29.7M 2.02%
+94,166
New +$29.5M
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$28.7M 1.96%
1,733,583
– –
DBVT
17
DBV Technologies
DBVT
$799M
$27.6M 1.88%
703,460
+65,000
+10% +$5.83M
ARGX icon
18
argenx
ARGX
$53.4B
$26.3M 1.8%
200,000
– –
KDMN
19
DELISTED
Kadmon Holdings, Inc.
KDMN
$26M 1.77%
6,205,882
– –
GOSS icon
20
Gossamer Bio
GOSS
$82.9M
$22.2M 1.51%
2,185,000
– –
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
$21.5M 1.46%
2,325,000
– –
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.6B
$21.1M 1.44%
250,000
– –
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$340M
$20.5M 1.39%
1,466,051
– –
ANAB icon
24
AnaptysBio
ANAB
$1.58B
$18.4M 1.25%
1,300,000
– –
BLU
25
DELISTED
BELLUS Health Inc.
BLU
$17.7M 1.21%
1,775,000
– –
1
2 3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Boxer Capital held 70 positions worth $1.47B, down 17% from $1.77B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital deployed $247M of net new capital in Q1 2020, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Revolution Medicines: 3,049,764 shares worth $66.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, an estimated $23.5M trimmed.

  • Boxer Capital's largest Q1 2020 buy was Revolution Medicines: 3,049,764 shares worth $66.8M.
  • Boxer Capital added most to Sage Therapeutics in Q1 2020, an estimated $68.5M increase.
  • Boxer Capital's biggest Q1 2020 reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, cutting an estimated $23.5M.
  • Boxer Capital fully exited Medicines Co in Q1 2020, selling an estimated $82.1M.
  • Boxer Capital's ten largest holdings make up 54% of its $1.47B portfolio in Q1 2020.
  • Boxer Capital opened 19 new positions and closed 8 in Q1 2020.
  • Boxer Capital's portfolio value fell 17% quarter-over-quarter to $1.47B.

Based on Boxer Capital's 13F filing for Q1 2020, filed 15 May 2020.